Evogene (NASDAQ:EVGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research report released on Friday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their price target on shares of Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, August 23rd.

Evogene Price Performance

NASDAQ:EVGN opened at $1.35 on Friday. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40. The firm has a market capitalization of $7.24 million, a price-to-earnings ratio of -0.30 and a beta of 1.36. The company’s 50-day moving average is $1.86 and its two-hundred day moving average is $3.64.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.